Business Context and Reporting Period
This Form 8-K Current Report was filed by Omeros Corporation on February 9, 2019. The report details corporate governance changes, specifically the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
- Board Expansion: The Board of Directors increased the number of directors to eight.
- New Appointment: Thomas F. Bumol, Ph.D., was appointed as a director effective immediately.
- Compensation: Dr. Bumol was granted a stock option to purchase 15,000 shares of common stock pursuant to the non-employee director compensation policy.
Outlook, Risks, and Management Commentary
Management Commentary: The appointment was made upon the recommendation of the Nominating and Governance Committee. Dr. Bumol brings 35 years of experience from Eli Lilly and Company and currently serves as Executive Director of the Allen Institute for Immunology. The Board determined he is an independent director under Nasdaq listing standards.
Regulatory Disclosure: A press release announcing the appointment was issued on February 12, 2019, under Regulation FD.
Risks and Contingencies: No specific financial risks or contingencies were disclosed in this filing. Dr. Bumol is indemnified under the Company's standard director indemnification agreement.
Investor Verification Checklist
- Verify the independence status of Dr. Bumol under Nasdaq listing standards.
- Review the terms of the stock option grant for 15,000 shares issued to Dr. Bumol.
- Confirm the expiration date of Dr. Bumol's initial term (2019 annual meeting of shareholders).
- Check for any subsequent committee assignments for Dr. Bumol, as none were assigned at the time of filing.